S Ling, F Ceban, LMW Lui, Y Lee, KM Teopiz… - CNS drugs, 2022 - Springer
Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …
Treatment‐resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility …
GM Goodwin, ST Aaronson, O Alvarez, M Atli… - Journal of Affective …, 2023 - Elsevier
Background COMP360 is a proprietary, synthetic formulation of psilocybin being developed for treatment-resistant depression (TRD), a burdensome, life-threatening illness with high …
N Zaki, L Chen, R Lane, T Doherty… - …, 2023 - nature.com
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to …
KS Kverno, E Mangano - Journal of psychosocial nursing and …, 2021 - journals.healio.com
Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered …
Abstract Background Treatment-resistant Depression (TRD) represents a widespread disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer …
Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects and unique mechanisms of action …
MK Jha, SJ Mathew - American Journal of Psychiatry, 2023 - Am Psychiatric Assoc
One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have …
Survival is a fundamental physiological drive, and neural circuits have evolved to prioritize actions that meet the energy demands of the body. This fine-tuning of goal-directed actions …